TB-500: what the evidence actually shows
TB-500 is a synthetic peptide corresponding to a short fragment of the naturally occurring protein thymosin beta-4.
Also known as TB500, thymosin beta-4 fragment.
Evidence and regulatory status
Animal or laboratory evidence only. No published human trial.
Not approved by the FDA for any indication. Prohibited in sport.
Half-life
No published human pharmacokinetic study reports a half-life for TB-500. Figures circulating on vendor and forum pages are not traceable to a human trial, so this page does not repeat them.
What published trials used
No published human dosing trial exists for TB-500.
Reported for reference only. What a trial administered under supervision is not a recommendation, and Gireta does not make one.
How much research exists
- PubMed records
- 26
- Tagged human
- 16
- Clinical trials
- 1
A PubMed search for TB-500 returns 26 records, of which 16 are tagged as human research and 1 is typed as a clinical trial.
Counted on . Counts drift, so the exact query is linked rather than described, and you can re-run it.
Common questions
- Is TB-500 the same as thymosin beta-4?
- They are not the same thing, and the distinction matters when reading the literature. Thymosin beta-4 is a 43-amino-acid protein with roughly a thousand PubMed records. TB-500 is a short synthetic fragment of it, with twenty-six. Search results for the protein are routinely presented as evidence for the fragment.
- What is the half-life of TB-500?
- No published human pharmacokinetic study reports a half-life for TB-500, so this page does not state one.
- Is TB-500 approved?
- No. TB-500 is not approved by the FDA for any indication, and it is prohibited in sport.
Sources
- TB-500 fragment characterisation · Drug Testing and Analysis, via PubMed, 2012
- Peptide therapies in musculoskeletal medicine · Sports Medicine, via PubMed, 2026
Related compounds
Peptides marketed for tissue repair
Grouped by the claim they are sold on rather than by chemistry. They are structurally unrelated: one is a gastric pentadecapeptide, the other a fragment of thymosin beta-4.
- BPC-157 BPC-157 is a synthetic pentadecapeptide derived from a sequence identified in human gastric juice.
Others graded preclinical here
Held to the same standard on this site. Each page prints its own literature counts, so where a record is typed as a clinical trial you can see it rather than take our word for the grade.
Planning a schedule?
Gireta turns a compound and a cadence into a twelve-week timeline with the reconstitution maths worked out and a monthly cost.
Plan a TB-500 scheduleLast reviewed .